(Q55001623)

English

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.

scientific article published on 8 May 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

author name string

V C Amann

1

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

D Hoffmann

2

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

J Mangana

3

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

R Dummer

4

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

S M Goldinger

5

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

publication date

8 May 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

Journal of the European Academy of Dermatology and Venereology

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

31

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

10

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

1638-1640

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1111%2FJDV.14268

21 January 2018

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJDV.14268

21 January 2018

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1111%2FJDV.14268

21 January 2018

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.14268

21 January 2018

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

1 reference

https://api.crossref.org/works/10.1111%2FJDV.14268

21 January 2018

Resistance to vemurafenib can be reversible after treatment interruption: a case report of a metastatic melanoma patient

1 reference

https://api.crossref.org/works/10.1111%2FJDV.14268

21 January 2018

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression

1 reference

https://api.crossref.org/works/10.1111%2FJDV.14268

21 January 2018

BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.14268

21 January 2018

Identifiers

10.1111/JDV.14268

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 June 2018

http://europepmc.org/abstract/MED/28401596

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55001623&oldid=1292180127"